OptiLight, by Lumenis, is the first and only light-based therapy to be approved by the United States Food and Drug Administration and Therapeutic Goods Administration for management of dry eye disease due to meibomian gland dysfunction (MGD), the leading cause of dry eye disease.
Designed by eye care professionals for eye care professionals, every element has been designed for a precise and comfortable dry eye procedure.
The patented optimal pulse technology (OPT) pen-like handpiece has been designed to get as close to the lid margin as possible and is customised to fit every curve and outline. OptiLight’s embedded settings, which are based on Lumenis’ clinically-validated treatment protocols, ensure safer and more effective patient procedures. The ergonomic intense pulsed light handpiece, with patented SapphireCool technology, is used for larger areas to successfully break dry eye’s vicious cycle of inflammation.
Contact: Lumenis (AUS) 1800 586 364
